APA (7th ed.) Citation

RT, K., SW, E., E, E., MA, S., & PJ, H. (2021). In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium. Pediatric blood & cancer, 68(2), e28772. https://doi.org/10.1002/pbc.28772

Chicago Style (17th ed.) Citation

RT, Kurmasheva, Erickson SW, Earley E, Smith MA, and Houghton PJ. "In Vivo Evaluation of the EZH2 Inhibitor (EPZ011989) Alone or in Combination with Standard of Care Cytotoxic Agents Against Pediatric Malignant Rhabdoid Tumor Preclinical Models-A Report from the Pediatric Preclinical Testing Consortium." Pediatric Blood & Cancer 68, no. 2 (2021): e28772. https://doi.org/10.1002/pbc.28772.

MLA (9th ed.) Citation

RT, Kurmasheva, et al. "In Vivo Evaluation of the EZH2 Inhibitor (EPZ011989) Alone or in Combination with Standard of Care Cytotoxic Agents Against Pediatric Malignant Rhabdoid Tumor Preclinical Models-A Report from the Pediatric Preclinical Testing Consortium." Pediatric Blood & Cancer, vol. 68, no. 2, 2021, p. e28772, https://doi.org/10.1002/pbc.28772.